Autopsy report · NCT01757197

Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 11 months before it started.
Ran for about 7 months before it stopped.
2 participants enrolled.
Results were posted on the registry 3 years 3 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Weill Medical College of Cornell University
Sponsor type: University, hospital or other
Conditions: Glucocorticosteroid Refractory Acute GVHD
Interventions: Toclizumab
Participants: 2
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.